Maternal RSV vaccine development. Where to from here?
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection and is responsible for a large proportion of infant morbidity and mortality worldwide. Most RSV-related deaths occur in children under six months, and the majority of these occur in low-income settings. To...
Main Authors: | Ahinsa Gunatilaka, Michelle L. Giles |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1955608 |
Similar Items
-
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
by: Pius I. Babawale, et al.
Published: (2025-01-01) -
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
by: Bryony Treston, et al.
Published: (2024-12-01) -
Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates
by: Georgios Papazisis, et al.
Published: (2024-08-01) -
Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland
by: Siobhan McCormack, et al.
Published: (2024-04-01) -
Maternal Effects of Respiratory Syncytial Virus Infection during Pregnancy
by: Sarahn M. Wheeler, et al.
Published: (2015-11-01)